{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T01:18:13Z","timestamp":1772846293854,"version":"3.50.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.clim.2016.07.008","type":"journal-article","created":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T13:10:10Z","timestamp":1469538610000},"page":"61-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Insights on methotrexate in psoriatic disease"],"prefix":"10.1016","volume":"172","author":[{"given":"Jacqueline E.","family":"Greb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ari M.","family":"Goldminz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice B.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clim.2016.07.008_bb0005","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1001\/archderm.1951.01570120023004","article-title":"Effect of aminopterin on epithelial tissues","volume":"64","author":"Gubner","year":"1951","journal-title":"A.M.A. Arch. Derm. Syphilol."},{"issue":"7","key":"10.1016\/j.clim.2016.07.008_bb0010","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1046\/j.1365-2230.2002.01146.x","article-title":"Traditional therapies: glucocorticoids, azathioprine, methotrexate, hydroxyurea","volume":"27","author":"Belgi","year":"2002","journal-title":"Clin. Exp. Dermatol."},{"issue":"3","key":"10.1016\/j.clim.2016.07.008_bb0015","first-page":"168","article-title":"Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis","volume":"65","author":"Tian","year":"2007","journal-title":"Bull. NYU Hosp. Jt. Dis."},{"issue":"7","key":"10.1016\/j.clim.2016.07.008_bb0020","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1056\/NEJMoa021359","article-title":"Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis","volume":"349","author":"Heydendael","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.clim.2016.07.008_bb0025","first-page":"116","article-title":"Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial","volume":"158","author":"Flytstrom","year":"2008","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"10.1016\/j.clim.2016.07.008_bb0030","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)","volume":"158","author":"Saurat","year":"2008","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"10.1016\/j.clim.2016.07.008_bb0035","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.1780270403","article-title":"Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis","volume":"27","author":"Willkens","year":"1984","journal-title":"Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.clim.2016.07.008_bb0040","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","article-title":"A randomized placebo-controlled trial of methotrexate in psoriatic arthritis","volume":"51","author":"Kingsley","year":"2012","journal-title":"Rheumatology"},{"issue":"Suppl. 1","key":"10.1016\/j.clim.2016.07.008_bb0045","first-page":"S41","article-title":"Methotrexate in psoriatic arthritis","volume":"71","author":"Mease","year":"2013","journal-title":"Bull. Hosp. Joint Dis."},{"issue":"4","key":"10.1016\/j.clim.2016.07.008_bb0050","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/ard.2011.152223","article-title":"Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study","volume":"71","author":"Baranauskaite","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"5 Suppl 61","key":"10.1016\/j.clim.2016.07.008_bb0055","first-page":"S132","article-title":"Use of methotrexate in patients with psoriatic arthritis","volume":"28","author":"Ceponis","year":"2010","journal-title":"Clin. Exp. Rheumatol."},{"issue":"4","key":"10.1016\/j.clim.2016.07.008_bb0060","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/ard.2009.113308","article-title":"Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis","volume":"69","author":"Lie","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.clim.2016.07.008_bb0065","first-page":"469","article-title":"Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort","volume":"35","author":"Chandran","year":"2008","journal-title":"J. Rheumatol."},{"issue":"6","key":"10.1016\/j.clim.2016.07.008_bb0070","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1172\/JCI116884","article-title":"The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation","volume":"92","author":"Cronstein","year":"1993","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.clim.2016.07.008_bb0075","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1172\/JCI1554","article-title":"Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5\u2032-nucleotidase-mediated conversion of adenine nucleotides","volume":"101","author":"Morabito","year":"1998","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.clim.2016.07.008_bb0080","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1161\/01.CIR.80.5.1400","article-title":"Increased adenosine concentration in blood from ischemic myocardium by AICA riboside. Effects on flow, granulocytes, and injury","volume":"80","author":"Gruber","year":"1989","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.clim.2016.07.008_bb0085","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/1529-0131(200003)43:3<656::AID-ANR23>3.0.CO;2-H","volume":"43","author":"Montesinos","year":"2000","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.clim.2016.07.008_bb0090","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.molmed.2013.03.005","article-title":"CD39 and CD73 in immunity and inflammation","volume":"19","author":"Antonioli","year":"2013","journal-title":"Trends Mol. Med."},{"issue":"2","key":"10.1016\/j.clim.2016.07.008_bb0095","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11302-016-9505-8","article-title":"Methotrexate up-regulates ecto-5\u2032-nucleotidase\/CD73 and reduces the frequency of T lymphocytes in the glioblastoma microenvironment","volume":"12","author":"Figueiro","year":"2016","journal-title":"Purinergic Signalling"},{"issue":"8","key":"10.1016\/j.clim.2016.07.008_bb0100","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1073\/pnas.1424792112","article-title":"Low expression of CD39 on regulatory T cells as a biomarker for resistance to methotrexate therapy in rheumatoid arthritis","volume":"112","author":"Peres","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.clim.2016.07.008_bb0105","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1046\/j.1365-2133.2003.05407.x","article-title":"Methotrexate inhibits proliferation and regulation of the expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 by cultured human umbilical vein endothelial cells","volume":"149","author":"Yamasaki","year":"2003","journal-title":"Br. J. Dermatol."},{"issue":"7","key":"10.1016\/j.clim.2016.07.008_bb0110","first-page":"273","article-title":"Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines","volume":"54","author":"Herman","year":"2005","journal-title":"Inflamm. Res. Off. J. Eur. Histamine Res. Soc."},{"issue":"2","key":"10.1016\/j.clim.2016.07.008_bb0115","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.clim.2004.09.001","article-title":"The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules","volume":"114","author":"Johnston","year":"2005","journal-title":"Clin. Immunol."},{"issue":"7","key":"10.1016\/j.clim.2016.07.008_bb0120","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.0906-6705.2004.00177.x","article-title":"Methotrexate markedly reduces the expression of vascular E-selectin, cutaneous lymphocyte-associated antigen and the numbers of mononuclear leucocytes in psoriatic skin","volume":"13","author":"Sigmundsdottir","year":"2004","journal-title":"Exp. Dermatol."},{"issue":"8","key":"10.1016\/j.clim.2016.07.008_bb0125","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/1529-0131(200008)43:8<1820::AID-ANR18>3.0.CO;2-D","volume":"43","author":"Kraan","year":"2000","journal-title":"Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.clim.2016.07.008_bb0130","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/rheumatology\/keg323","article-title":"Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis","volume":"42","author":"Gerards","year":"2003","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.clim.2016.07.008_bb0135","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1172\/JCI2676","article-title":"Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells","volume":"102","author":"Genestier","year":"1998","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.clim.2016.07.008_bb0140","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1247\/csf.28.113","article-title":"The induction of apoptosis by methotrexate in activated lymphocytes as indicated by fluorescence hyperpolarization: a possible model for predicting methotrexate therapy for rheumatoid arthritis patients","volume":"28","author":"Herman","year":"2003","journal-title":"Cell Struct. Funct."},{"issue":"5","key":"10.1016\/j.clim.2016.07.008_bb0145","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1016\/S0041-1345(98)00648-4","article-title":"Activation-dependent lymphocyte apoptosis induced by methotrexate","volume":"30","author":"Paillot","year":"1998","journal-title":"Transplant. Proc."},{"issue":"7","key":"10.1016\/j.clim.2016.07.008_bb0150","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.biopha.2010.01.007","article-title":"Therapeutic efficacy of experimental rheumatoid arthritis with low-dose methotrexate by increasing partially CD4+CD25+ Treg cells and inducing Th1 to Th2 shift in both cells and cytokines","volume":"64","author":"Xinqiang","year":"2010","journal-title":"Biomed. Pharmacother. Biomed. pharmacotherapie"},{"issue":"8","key":"10.1016\/j.clim.2016.07.008_bb0155","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1007\/s00296-011-1867-1","article-title":"Methotrexate attenuates the Th17\/IL-17 levels in peripheral blood mononuclear cells from healthy individuals and RA patients","volume":"32","author":"Li","year":"2012","journal-title":"Rheumatol. Int."},{"issue":"5","key":"10.1016\/j.clim.2016.07.008_bb0160","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.4049\/jimmunol.167.5.2911","article-title":"Methotrexate suppresses NF-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation","volume":"167","author":"Majumdar","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2016.07.008_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdermsci.2016.03.007","article-title":"Methotrexate improves pro- and anti-atherogenic genomic expression in psoriatic skin","author":"Goldminz","year":"2016","journal-title":"J. Dermatol. Sci."},{"issue":"4","key":"10.1016\/j.clim.2016.07.008_bb0170","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.it.2012.11.005","article-title":"The IL-23\/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses","volume":"34","author":"Lowes","year":"2013","journal-title":"Trends Immunol."},{"issue":"5","key":"10.1016\/j.clim.2016.07.008_bb0175","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/eji.200535503","article-title":"IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis","volume":"36","author":"Wolk","year":"2006","journal-title":"Eur. J. Immunol."},{"issue":"5","key":"10.1016\/j.clim.2016.07.008_bb0180","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00109-009-0457-0","article-title":"IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not","volume":"87","author":"Wolk","year":"2009","journal-title":"J. Mol. Med."},{"issue":"7","key":"10.1016\/j.clim.2016.07.008_bb0185","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4\u2212CD8\u2212 entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.clim.2016.07.008_bb0190","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1001\/jamadermatol.2015.0452","article-title":"CCL20 and IL22 messenger RNA expression after adalimumab vs methotrexate treatment of psoriasis: a randomized clinical trial","volume":"151","author":"Goldminz","year":"2015","journal-title":"JAMA Derm."},{"issue":"7","key":"10.1016\/j.clim.2016.07.008_bb0195","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1600-0625.2011.01308.x","article-title":"A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis","volume":"20","author":"Armstrong","year":"2011","journal-title":"Exp. Dermatol."},{"issue":"Suppl. 2","key":"10.1016\/j.clim.2016.07.008_bb0200","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2133.2008.08780.x","article-title":"Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach","volume":"159","author":"Spah","year":"2008","journal-title":"Br. J. Dermatol."},{"issue":"5","key":"10.1016\/j.clim.2016.07.008_bb0205","doi-asserted-by":"crossref","first-page":"284","DOI":"10.7150\/ijms.7.284","article-title":"Pathogenic mechanisms shared between psoriasis and cardiovascular disease","volume":"7","author":"Ghazizadeh","year":"2010","journal-title":"Int. J. Med. Sci."},{"issue":"7","key":"10.1016\/j.clim.2016.07.008_bb0210","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/jid.2010.103","article-title":"Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions","volume":"130","author":"Davidovici","year":"2010","journal-title":"J. Invest. Dermatol."},{"issue":"12","key":"10.1016\/j.clim.2016.07.008_bb0215","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1038\/jid.2014.268","article-title":"IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood","volume":"134","author":"Wang","year":"2014","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.clim.2016.07.008_bb0220","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaci.2012.04.024","article-title":"IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis","volume":"130","author":"Krueger","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"issue":"9313","key":"10.1016\/j.clim.2016.07.008_bb0225","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(02)08213-2","article-title":"Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study","volume":"359","author":"Choi","year":"2002","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.clim.2016.07.008_bb0230","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2796.2012.02593.x","article-title":"Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study","volume":"273","author":"Ahlehoff","year":"2013","journal-title":"J. Intern. Med."},{"issue":"19","key":"10.1016\/j.clim.2016.07.008_bb0235","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1001\/jama.2013.4695","article-title":"Do TNF inhibitors reduce the risk of myocardial infarction in psoriasis patients?","volume":"309","author":"Armstrong","year":"2013","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.clim.2016.07.008_bb0240","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1001\/archdermatol.2012.2502","article-title":"Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis","volume":"148","author":"Wu","year":"2012","journal-title":"Arch. Dermatol."},{"issue":"9","key":"10.1016\/j.clim.2016.07.008_bb0245","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.amjcard.2011.06.054","article-title":"Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease","volume":"108","author":"Micha","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.clim.2016.07.008_bb0250","unstructured":"Ridker P. Cardiovascular Inflammation Reduction Trial (CIRT). (ClinicalTrials.gov [online]. (NLM Identifier: NCT01594333))."},{"issue":"5","key":"10.1016\/j.clim.2016.07.008_bb0255","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.jaad.2008.11.906","article-title":"Methotrexate and psoriasis: 2009 National Psoriasis Foundation consensus conference","volume":"60","author":"Kalb","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"issue":"9","key":"10.1016\/j.clim.2016.07.008_bb0260","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum."},{"issue":"11","key":"10.1016\/j.clim.2016.07.008_bb0265","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/00008571-200411000-00004","article-title":"Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis","volume":"14","author":"Dervieux","year":"2004","journal-title":"Pharmacogenetics"},{"issue":"9","key":"10.1016\/j.clim.2016.07.008_bb0270","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1002\/art.22032","article-title":"Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis","volume":"54","author":"Wessels","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.clim.2016.07.008_bb0275","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1002\/art.22640","article-title":"A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis","volume":"56","author":"Wessels","year":"2007","journal-title":"Arthritis Rheum."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661616301838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661616301838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T07:24:20Z","timestamp":1536564260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661616301838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":55,"alternative-id":["S1521661616301838"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2016.07.008","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insights on methotrexate in psoriatic disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2016.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}